GT Medical, Theragenics Join Forces to Expand Access to Cesium-131

GT Medical Technologies Inc. (GT MedTech) has crafted a strategic distribution partnership with Theragenics Corporation that aims to expand physician access to Cesium-131 seeds, thereby providing greater flexibility to support their brachytherapy procedural needs.

“We are very pleased to align with Theragenics, a global brachytherapy leader, to propel the field of cancer care forward.” GT Medical Technologies CEO Per Langoe said. “This partnership ensures continued access to Cesium-131 for clinicians and patients, addressing critical healthcare needs.”
 
Through the partnership, Theragenics will become the exclusive distributor of Cesium-131 brachytherapy seeds and carriers used for various non-brain cancer related treatments including prostate cancer. GT MedTech, the sole manufacturer of Cesium-131, will continue to focus on expanding adoption of the company’s U.S. Food and Drug Administration (FDA)-cleared GammaTile therapy for treating operable brain tumors in the United States.
 
Cesium-131 is a common isotope used with low dose rate [LDR] brachytherapy, a radiation treatment where tiny radioactive seeds are implanted directly into or adjacent to a tumor. This approach delivers a high radiation dose to cancer cells while minimizing damage to surrounding healthy tissues.
 
“This partnership reinforces Theragenics’ unwavering commitment to brachytherapy,” Theragenics Interventional President Michael Krachon stated. “With the addition of Cesium-131 to our portfolio, we can more comprehensively support the clinical needs of the brachytherapy community and further expand our efforts to raise awareness of brachytherapy as a viable treatment option for men battling prostate cancer.”
 
As the exclusive manufacturer of Cesium-131, GT MedTech is dedicated to expanding its utilization to advance cancer care. Concurrently, GT MedTech is focused on driving the evidence-based adoption of GammaTile, aiming to establish a new standard of care for operable brain tumors.*
 
Driven to raise the standard of care, a team of brain tumor specialists formed GT Medical Technologies. GammaTile is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 100 institutions. 
 
Theragenics is a pioneer in brachytherapy, offering minimally invasive, radiation-based treatments for prostate and other cancers. Through its subsidiaries, the company designs and delivers a portfolio of vascular access, specialty needles products, and surgical devices, serving critical needs across interventional radiology, interventional cardiology, and vascular surgery.